Advertisement
Advertisement
U.S. markets close in 4 hours 57 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cyclacel Pharmaceuticals, Inc. (CYCCP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
16.58+0.38 (+2.35%)
As of 09:30AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close16.20
Open16.58
Bid15.50 x 800
Ask18.25 x 900
Day's Range16.58 - 17.00
52 Week Range6.20 - 22.58
Volume150
Avg. Volume1,638
Market Cap31.526M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-2.05
Earnings DateN/A
Forward Dividend & Yield0.60 (4.00%)
Ex-Dividend DateJul 20, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CYCCP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cyclacel Pharmaceuticals, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    15 hours agoMorningstar
View more
  • Thomson Reuters StreetEvents

    Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call

    Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    - Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell

  • GlobeNewswire

    Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

    BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call:

Advertisement
Advertisement